Previous GWAS studies have reported significant associations between various common
SNPs and prostate cancer risk using cases unselected for family history. How these variants …

PURPOSE Prostate cancer (PCa) is highly heritable. No validated PCa risk model currently
exists. We therefore sought to develop a genetic risk model that can provide personalized …

The transferability and clinical value of genetic risk scores (GRSs) across populations
remain limited due to an imbalance in genetic studies across ancestrally diverse …

Importance Few studies have evaluated the association between a single-nucleotide
polymorphism–based genetic risk score (GRS) and patient age at prostate cancer (PCa) …

Purpose Single-nucleotide polymorphism (SNP) panel tests have been proposed for use in
the detection of, and prediction of risk for, prostate cancer and as prognostic indicator in …

Objectives To develop and validate a genetic tool to predict age of onset of aggressive
prostate cancer (PCa) and to guide decisions of who to screen and at what age. Design …

Prostate cancer heritability is attributed to a combination of rare, moderate to highly
penetrant genetic variants as well as commonly occurring variants conferring modest risks …

Objective To determine to what extent prostate cancer (PCa) risk prediction is improved by
adding prostate-specific antigen (PSA) to a baseline model including genetic risk. Methods …

Prostate cancer (PCa) is a major health care problem because of its high prevalence, health‐
related costs, and mortality. Epidemiological studies have suggested an important role of …

Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate
cancer. Our model developed in Europeans (PHS46) showed reduced performance in men …